[Anti-CGRP-based Migraine Medications: A Comprehensive Overview].

Area of Science:

• Neurology
• Pharmacology
• Medical Science

Background:

• Calcitonin gene-related peptide (CGRP) identified in the 1990s as crucial in migraine pathophysiology.
• CGRP's discovery shifted migraine treatment paradigms from non-specific drugs to targeted therapies.
• Previous migraine prophylactics had limited efficacy and significant side effects.

Purpose of the Study:

• To review the current research on CGRP-specific migraine therapies.
• To present real-world data on CGRP(-receptor) antibodies and gepants post-launch.
• To highlight advancements in migraine treatment strategies.

Main Methods:

• Review of extensive clinical trial data for CGRP-specific treatments.
• Analysis of real-world evidence from early clinical practice.
• Synthesis of current research on monoclonal CGRP(-receptor) antibodies and gepants.

Main Results:

• Monoclonal CGRP(-receptor) antibodies demonstrate safety, tolerability, and efficacy in episodic and chronic migraine prophylaxis.
• Gepants show similar positive outcomes, serving as acute treatment alternatives and prophylactic options.
• CGRP-specific therapies represent a significant advancement over older, non-specific migraine medications.

Conclusions:

• CGRP-specific therapies, including monoclonal antibodies and gepants, have transformed migraine management.
• These targeted treatments offer effective and well-tolerated options for both acute and prophylactic migraine care.
• Real-world data supports the clinical trial findings, confirming the value of CGRP-targeted approaches.